Layman, R. M., LoRusso, P., Mukohara, T., Park, Y. H., Rugo, H. S., Yan, F., Im, S., Yonemori, K., Sommerhalder, D., Yamashita, T., Kim, G. M., Hara, F., Kim, S., Wang, S., Kim, J. H., Badhrinarayanan, S., Skoura, A., Kent, S., Li, M., Hamilton, E. P. (2026). Long-term safety results and adverse event (AE) management recommendations in patients with ER+/HER2− metastatic breast cancer (mBC) receiving prifetrastat, a first-in-class KAT6 inhibitor, at the recommended phase 3 dose (RP3D) of 5 mg once-daily (QD).. Journal of Clinical Oncology. https://doi.org/10.1200/jco.2026.44.16_suppl.1068